NEW BRUNSWICK, N.J. — Johnson & Johnson has voluntarily
recalled about 2.45 million packages of Tylenol Cold Multi-Symptom Nighttime
Rapid Release Gelcaps after discovering a higher level than expected of the
chemical chlorpheniramine ammonio acetate (CPAA), according to The
The company initiated the recall as a precaution and no
safety concerns have been associated with CPAA.
action is required by consumers or healthcare providers and consumers can
continue to use the product, the company said in a statement